The Relationship among Bowel [18]F-FDG PET Uptake, Pathological Complete Response, and Eating Habits in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Rita De Sanctis(Humanitas University), C. Benvenuti, Alessandro Viganò(Sapienza University of Rome), Lidija Antunovic(Humanitas University), Mariangela Gaudio(Humanitas University), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Manuela Pastore(IRCCS Humanitas Research Hospital), Arturo Chiti(Vita-Salute San Raffaele University), Elisabetta Farina(Don Carlo Gnocchi Foundation), Armando Santoro(IRCCS Humanitas Research Hospital), Chiara Miggiano(Humanitas University)
Cited by 7
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532